12:00 AM
Feb 22, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LJP 394: Phase II/III

LJPC presented additional data from its Phase II/III trial showing that in patients whose antibodies had high affinity for LJP 394, there was a significant increase in time to renal flare (the primary end point) with LJP 394...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >